匹马范色林

Description

Pimavanserin · CAS 706779-91-1 · C25H34FN3O2. UNII JZ963P0DIK. Boiling Point: 604.2±55.0; Melting Point: 117-119; Dissociation Constants: 13.52±0.46.

Identification

CAS Registry Number	706779-91-1
PubChem CID	10071196
Molecular formula	C25H34FN3O2
IUPAC name	1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
UNII (FDA)	JZ963P0DIK

Computed Descriptors

Molecular Weight	427.6
XLogP3	4.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	8
Exact Mass	427.26350550
Monoisotopic Mass	427.26350550
Topological Polar Surface Area	44.8
Heavy Atom Count	31
Formal Charge	0

Physical & Chemical Properties

Boiling Point	604.2±55.0
Melting Point	117-119
Dissociation Constants	13.52±0.46

Documented Uses

• Pimavanserin is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
• Pimavanserin is an atypical antipsychotic that received FDA approval in the U.S. in 2016 for hallucinations and delusions that accompany Parkinson disease psychosis (PDP). It is the first and only FDA-approved medication for PDP. It had initially received Breakthrough Therapy status from the FDA in 2014. In the phase III clinical trial that paved the way for FDA approval, patients receiving pimavanserin demonstrated significant improvement in the frequency and/or severity of hallucinations and/or delusions without
• Pimavanserin is an atypical antipsychotic used in the treatment of hallucinations and delusions in patients with Parkinson disease and psychosis. Use of pimavanserin is associated with a low rate of serum enzyme elevations during therapy but it has not been linked to instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Antipsychotic Agents; Serotonin 5-HT2 Receptor Antagonists
• Avoid grapefruit products. Dose adjustment may be necessary if taking grapefruit products or other CYP3A4 inhibitors.
• Avoid St. John's Wort. This may induce the CYP3A4 metabolism of pimavanserin, which may cause reduced efficacy.

Synonyms

Pimavanserin; 706779-91-1; ACP-103; pimavanserina; pimavanserine; JZ963P0DIK; CHEBI:133017; DTXSID90990906; 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide; ACP 103; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide; 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea; pimavanserinum; 1-((4-fluorophenyl)methyl)-1-(1-methylpiperidin-4-yl)-3-((4-(2-methylpropoxy)phenyl)methyl)urea; RefChem:59074

Frequently Asked Questions

What are the CAS number and molecular formula of Pimavanserin?

CAS 706779-91-1; molecular formula C25H34FN3O2; molecular weight — g/mol.

What other names is Pimavanserin known by?

Pimavanserin, 706779-91-1, ACP-103, pimavanserina, pimavanserine, JZ963P0DIK.

What are the key physical properties of Pimavanserin?

Boiling Point: 604.2±55.0; Melting Point: 117-119; Dissociation Constants: 13.52±0.46.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.